Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.55 |
| ▸ | HTR1A | P08908 | 3/20 | 0.55 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | DRD3 | P35462 | 3/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | DRD5 | P21918 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8011291 | 0.86 | DRD2 (0.65) | DRD2HTR1AHTR2ADRD3DRD1 | |
| SCHEMBL8001944 | 0.86 | DRD2 (0.65) | DRD2HTR1AHTR2ADRD3DRD1 | |
| SCHEMBL9967731 | 0.85 | DRD2 (0.68) | DRD2HTR1AHTR2ADRD3DRD1 | |
| SCHEMBL9967721 | 0.85 | PRCP (0.48) | DRD2SIGMAR1 | |
| SCHEMBL9967730 | 0.85 | DRD2 (0.64) | DRD2SIGMAR1 | |
| SCHEMBL8001978 | 0.84 | DRD2 (0.63) | DRD2HTR1AHTR2ADRD3DRD1 | |
| SCHEMBL8571166 | 0.83 | DRD2 (0.59) | DRD2HTR1AHTR2ADRD3DRD1 | |
| SCHEMBL11932474 | 0.83 | DRD2 (0.68) | DRD2HTR1AHTR2ADRD3DRD1 | |
| SCHEMBL8012789 | 0.82 | DRD2 (0.60) | DRD2HTR1AHTR2ADRD3DRD1 | |
| SCHEMBL256669 | 0.82 | DRD2 (0.58) | DRD2HTR1AHTR2ADRD3DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447122-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2016-09-20 | — | — | US | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-8894970-B2 | Arginase inhibitors and methods of use thereof | CORRIDOR PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20120171116-A1 | Arginase Inhibitors and Methods of Use Thereof | CORRIDOR PHARMACEUTICALS, INC. | 2012-07-05 | — | — | US | disclosed |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | BAYER CROPSCIENCE AG (DE) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171116-A1 | Arginase Inhibitors and Methods of Use Thereof | ARG1, ARG2, PRMT1 | DRD2 4451/4885HTR1A 3657/4885HTR2A 3933/4885 |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | DHPS, FDPS, DPYD | DRD2 1749/4885HTR1A 3423/4885HTR2A 4130/4885 |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | DHPS, FDPS, DPYD | DRD2 1749/4885HTR1A 3423/4885HTR2A 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.